Citations

Showing 10 of 108104 citations.

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials
Jeter, Joanne, Bowles, Tawnya L. , Curiel‐Lewandrowski, Clara , Filipp, Fabian V. , Geskin, Larisa J. , Brewer, Jerry D., Gershenwald, Jeffrey E. , Chu, Emily Y. , Kirkwood, John M. , Funchain, Pauline , Fisher, David E. , Kendra, Kari , Marghoob, Ashfaq A. , Chen, Suephy C. , Ming, Michael E. , Albertini, Mark R. , Vetto, John T. , Margolin, Kim , Hay, Jennifer L. , Ellis, Darrel L., Kashani–Sabet, Mohammed , Mangold, Aaron R. , Nelson, Kelly C. , Powers, Jennifer G. , Sahni, Debjani, Sekulić, Aleksandar , Sondak, Vernon K. , Wei, Maria L. , Thompson, John A. , Weinstock, Martin A. , Cassidy, Pamela B. , Filipp, Fabian V , Mangold, A R , Funchain, Pauline , Jeter, Joanne , Swetter, Susan M. , ABDEL‐MALEK, ZALFA A. , Arbiser, Jack L. , Box, Neil F. , Pagoto, Sherry , Grossman, Douglas , Markovic, Svetomir N. , Robinson, June K. , Zager, Jonathan S. , Dellavalle, Robert Paul , Leachman, Sancy A.

Mayo Clinic

Cancer | October 5, 2018 | Volume: 125 | Issue: 1 | Pages: 18-44

10.1002/cncr.31719 | PMID 30281145 Get It

Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival and, as these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge toward the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to reduce dramatically both the morbidity and the high costs associated with treating patients who have metastatic disease. In this work, scientific and clinical melanoma experts from the national Melanoma Prevention Working Group, composed of National Cancer Trials Network investigators, discuss research aimed at discovering and developing (or repurposing) drugs and natural products for the prevention of melanoma and propose an updated pipeline for translating the most promising agents into the clinic. The mechanism of action, preclinical data, epidemiological evidence, and results from available clinical trials are discussed for each class of compounds. Selected keratinocyte carcinoma chemoprevention studies also are considered, and a rationale for their inclusion is presented. These data are summarized in a table that lists the type and level of evidence available for each class of agents. Also included in the discussion is an assessment of additional research necessary and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years.
Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single‐Center Cohort of Sixty‐One Patients
Richter, Michael , Crowson, Cynthia S. , Kottschade, Lisa A. , Finnes, Heidi D. , Thanarajasingam, Uma , Richter, Michael D, Crowson, Cynthia, Markovic, Svetomir N.

Mayo Clinic

Arthritis & Rheumatology | October 5, 2018 | Volume: 71 | Issue: 3 | Pages: 468-475

10.1002/art.40745 | PMID 30281202 Get It

ObjectiveTo describe the prevalence, clinical presentation, and management of rheumatic immune‐related adverse effects (Rh‐irAEs) from immune checkpoint inhibitor (ICI) therapy.MethodsFrom a database of all patients who received any ICI at the Mayo Clinic Rochester, Minnesota campus between January 1, 2011 and March 1, 2018, we retrospectively identified those with Rh‐irAEs, using diagnostic codes, search terms, and manual chart review.ResultsOf the 1,293 patients who received any ICI, Rh‐irAEs were clinically diagnosed in 43. Eighteen patients with Rh‐irAEs who received ICI therapy elsewhere were also analyzed. Clinical syndromes included inflammatory arthritis (n = 34 [prevalence 2%]), myopathy (n = 10), and other rheumatic syndromes (n = 17). Inflammatory arthritis was most commonly polyarticular, and glucocorticoid treatment was required in 26 patients (76%). The mean ± SD duration of treatment was 18 ± 18 weeks. Five patients (15%) also received disease‐modifying antirheumatic drugs, and ICI therapy had to be discontinued in 3 patients (9%). Myopathy was treated with glucocorticoids in all cases (mean ± SD treatment duration 15 ± 17 weeks) and led to 2 deaths and permanent ICI discontinuation in 9 patients (90%). Other syndromes included connective tissue diseases, vasculitis, polymyalgia rheumatica–like syndrome, and flare of preexisting rheumatic disease. Most (71%) were treated with immunosuppression, with 12% requiring ICI discontinuation.ConclusionThis study represents the largest cohort of patients with Rh‐irAEs reported to date. Most patients received long courses of immunosuppressive treatment, although discontinuation of ICI therapy was required in only a minority.
Partial tubal devascularisation: a novel procedure for tubal conservation in ectopic pregnancy
Gayar, Ahmed G., Abdelbadee, Ahmed Y. , Afifi, Ahmed , Nassr, Ahmed A. , Shazly, Sherif A.

Mayo Clinic

Journal of Obstetrics and Gynaecology | October 5, 2018 | Volume: 39 | Issue: 2 | Pages: 202-205

10.1080/01443615.2018.1476472 | PMID 30286665 Get It

Comparing the International Classification of Functioning, Disability, and Health Core Sets for Hearing Loss and Otorhinolaryngology/Audiology Intake Documentation at Mayo Clinic
Alfakir, Razan , Leeuwen, Lisette M. van , Pronk, Marieke , Kramer, Sophia E. , Zapala, David A., van Leeuwen, Lisette M, Alfakir, Razan

Mayo Clinic

Ear & Hearing | October 5, 2018 | Volume: 40 | Issue: 4 | Pages: 858-869

10.1097/aud.0000000000000662 | PMID 30289788 Get It

Objectives: The International Classification of Functioning, Disability, and Health (ICF) Core Sets for Hearing Loss (CSHL) consists of short lists of categories from the entire ICF classification that are thought to be the most relevant for describing the functioning of persons with hearing loss. A comprehensive intake that covers all factors included in the ICF CSHL holds the promise of developing a tailored treatment plan that fully complements the patient’s needs. The Comprehensive CSHL contains 117 categories and serves as a guide for multiprofessional, comprehensive assessment. The Brief CSHL includes 27 of the 117 categories and represents the minimal spectrum of functioning of persons with HL for single-discipline encounters or clinical trials. The authors first sought to benchmark the extent to which Audiologist (AUD) and Otorhinolaryngologist (ORL) discipline-specific intake documentation, as well as Mayo Clinic’s multidisciplinary intake documentation, captures ICF CSHL categories. Design: A retrospective study design including 168 patient records from the Department of Otorhinolaryngology/Audiology of Mayo Clinic in Jacksonville, Florida. Anonymized intake documentation forms and reports were selected from patient records filed between January 2016 and May 2017. Data were extracted from the intake documentation forms and reports and linked to ICF categories using pre-established linking rules. “Overlap,” defined as the percentage of ICF CSHL categories represented in the intake documentation, was calculated across document types. In addition, extra non–ICF CSHL categories (ICF categories that are not part of the CSHL) and extra constructs (constructs that are not part of the ICF classification) found in the patient records were described. Results: The total overlap of multidisciplinary intake documentation with ICF CSHL categories was 100% for the Brief CSHL and 50% for the Comprehensive CSHL. Brief CSHL overlap for discipline-specific documentation fell short at 70% for both AUD and ORL. Important extra non–ICF CSHL categories were identified and included “sleep function” and “motor-related functions and activities,” which mostly were reported in relation to tinnitus and vestibular disorders. Conclusion: The multidisciplinary intake documentation of Mayo Clinic showed 100% overlap with the Brief CSHL, while important areas of nonoverlap were identified in AUD- and ORL-specific reports. The ICF CSHL provides a framework for describing each hearing-impaired individual’s unique capabilities and needs in ways currently not documented by audiological and otological evaluations, potentially setting the stage for more effective individualized patient care. Efforts to further validate the ICF CSHL may require the involvement of multidisciplinary institutions with commonly shared electronic health records to adequately capture the breath of the ICF CSHL.
Ten-Year Follow-Up of Off-Pump and On-Pump Multivessel Coronary Artery Bypass Grafting: MASS III
Hueb, Whady , Rezende, Paulo Cury , Soares, Paulo Rogério , Favarato, Desidério , Garzillo, Cibele Larrosa , Jatene, Fábio Biscegli , Gersh, Bernard J. , Lima, Eduardo Gomes , Ramires, José Antônio Franchini , Filho, Roberto Kalil

Mayo Clinic

Angiology | October 5, 2018 | Volume: 70 | Issue: 4 | Pages: 337-344

10.1177/0003319718804402 | PMID 30286625 Get It

It was a randomized trial, and 308 patients undergoing revascularization were randomly assigned: 155 to off-pump coronary artery bypass (OPCAB) and 153 to on-pump coronary artery bypass (ONCAB). End points were freedom from death, myocardial infarction, revascularization, and cerebrovascular accidents. The rates for 10-year, event-free survival for ONCAB versus OPCAB were 69.6% and 64%, (hazard ratio [HR]: 0.88; 95% confidence interval [CI] 0.86-1.02; P = .41), respectively. Adjusted Cox proportional hazard ratio was similar (HR: 0.92; 95% CI 0.61-1.38, P = .68). A difference occurred between the duration of OPCAB and ONCAB, respectively (4.9 ± 1.5 vs 6.6 ± 1.1 h, P < .001). Statistical differences occurred between OPCAB and ONCAB in the length of intensive care unit (ICU) stay (20 ± 2.5 vs 48 ± 10 hours, P < .001), time to extubation (5.5 ± 4.2 vs 10.2 ± 3.5 hours, P < .001), hospital stay (6.7 ± 1.4 vs 9.2 ± 1.3 days, P < .001), higher incidence of atrial fibrillation (AF; 33 vs 5 patients, P < .001), and blood requirements (46 vs 64 patients, P < .001). Grafts per patient was higher in ONCAB (3.15 vs 2.55 grafts, P < .001). No difference existed between the groups in primary composite end points at 10-year follow-up. Although OPCAB surgery was related to a lower number of grafts and higher incidence of AF, it had no effects related to long-term outcomes.
Facial Malformation in Crouzon’s Syndrome Is Consistent with Cranial Base Development in Time and Space
Lu, Xiaona , Forte, Antonio J. , Sawh‐Martinez, Rajendra , Madari, Sarika, Wu, Robin T. , Cabrejo, Raysa, Steinbacher, Derek M., Alperovich, Michael , Alonso, Nivaldo , Persing, John A. , Forte, Antonio Jorge

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | October 5, 2018 | Volume: 6 | Issue: 10 | Pages: e1963

10.1097/gox.0000000000001963 | PMID 30534503 Get It

Background:In Crouzon’s syndrome, cranial base deformities begin sequentially in the anterior cranial fossa initially, and later to the posterior cranial base. Facial characteristics are likely related to cranial base development. The temporal correlation between cranial base development and facial features is in need of clarification in Crouzon’s patients, to clarify initial sites of deformity, which may impact surgical decision making.Methods:Thirty-six computed tomography scans of unoperated Crouzon’s syndrome patients and 54 controls were included and divided into 5 age-subgroups. All the planes used for analysis were set as perpendicular to a defined “midplane” to offset the confounding factor caused by potential asymmetry.Results:The angle between Sella-Nasion plane and Frankfort horizontal plane was significantly increased before 6 months of age (P= 0.014), with an average 70% (P< 0.001) increase ultimately into adulthood. The angle between SN and maxillary plane and the angle between Sella-Nasion and occlusal planes increased consistently through infancy to adulthood (124% and 42%, respectively, bothP< 0.001). The relative angle of mandibular plane to Frankfort horizontal plane increased before 6 months (28%,P= 0.007) with a peak timeframe from 2 to 18 years. Facial lateral curvature related measurements indicate the whole face is inclined posteriorly and inferiorly direction in relation to the anterior cranial base.Conclusion:Crouzon’s facial malformation development is synchronous and positionally correlational with cranial base deformity. It transmitted from orbit to mandible, with the most evident morphologic changes are in the orbit and midface.
Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache
Nation, Kelsey , Nation, Kelsey M , Navratilova, Edita , Dodick, David W. , Porreca, Frank

Mayo Clinic

Cephalalgia | October 5, 2018 | Volume: 39 | Issue: 5 | Pages: 617-625

10.1177/0333102418804157 | PMID 30286616 Get It

Background Loss of conditioned pain modulation/diffuse noxious inhibitory controls has been demonstrated in patients with migraine and medication overuse headache. We hypothesized that exposure to acute migraine medications may lead to dysregulation of central pain modulatory circuits that could be revealed by evaluating diffuse noxious inhibitory controls and that prior noxious stimulus is required for a loss of the diffuse noxious inhibitory control response in rats exposed to these medications. Methods Rats were “primed” by continuous infusion of morphine or one of two doses of sumatriptan. Diffuse noxious inhibitory control was evaluated at the end of drug-priming (day 7) and again after sensory thresholds returned to baseline (day 21). The Randall-Selitto hindpaw pressure test was used as the test stimulus and forepaw capsaicin injection served as the conditioning stimulus. Results Morphine-primed rats showed opioid-induced hyperalgesia accompanied by a loss of diffuse noxious inhibitory controls on day 7. Sumatriptan-primed rats did not develop hyperalgesia or loss of diffuse noxious inhibitory controls on day 7. Morphine-primed and high-dose sumatriptan-primed rats only had a loss of diffuse noxious inhibitory control on day 21 if they received a capsaicin injection on day 7. Conclusions Prolonged exposure to migraine treatments followed by an acute nociceptive stimulation caused long-lasting alterations in descending pain modulation, shown by a loss of diffuse noxious inhibitory controls. Morphine was more detrimental than sumatriptan, consistent with clinical observations of higher medication overuse headache risk with opioids. These data suggest a mechanism of medication overuse headache by which migraine medications combined with repeated episodes of pain may amplify the consequences of nociceptor activation and increase the probability of future migraine attacks as well as risk of medication overuse headache.
Population Frequency of Serous Tubal Intraepithelial Carcinoma (STIC) in Clinical Practice Using SEE-Fim Protocol
Samimi, Goli , Trabert, Britton , Geczik, Ashley M. , Trabert, B , Duggan, Máire A. , Sherman, Mark E.

Mayo Clinic

JNCI Cancer Spectrum | October 4, 2018 | Volume: 2 | Issue: 4 | Pages: No page available

10.1093/jncics/pky061 | PMID 31360879 Get It

Abstract Frequent detection of serous tubal intraepithelial carcinoma (STIC) among BRCA1/2 mutation carriers undergoing risk-reducing surgery prompted the hypothesis that many adnexal high-grade serous carcinomas (HGSCs) arise from the fallopian tube, rather than the ovary, as supposed. The changing paradigm has important implications for HGSC prevention. Most data related to the frequency of STIC are derived from case series and estimates vary widely. Therefore, we analyzed population-based data from 10 523 surgeries including salpingectomy (Jan 2014–Dec 2016) that were examined using the “Sectioning and Extensively Examining the Fimbria” protocol, which optimizes STIC detection. Overall, STIC was detected in 40 (0.38%) specimens, including 32 diagnosed with concurrent gynecologic cancer. STIC was detected in 8 (<0.01%) of 9392 cases with benign diagnoses. We conclude that the relative rarity of STIC diagnoses in routine pathology practice has critical implications for research aiming to elucidate the pathogenesis of HGSC and developing prevention strategies.
Current and Future Treatments for Graves’ Disease and Graves’ Ophthalmopathy
Kotwal, Anupam , Stan, Marius N. , Stan, Marius, Kudva, Yogish C , Stan, Marius N

Mayo Clinic

Hormone and Metabolic Research | October 4, 2018 | Volume: 50 | Issue: 12 | Pages: 871-886

10.1055/a-0739-8134 | PMID 30286486 Get It

AbstractThe course and pathogenesis of Graves’ disease and Graves’ ophthalmopathy are interdependent, influencing each other’s therapeutic choices. Multiple factors including geographic location, access to medical services, patient and physician preferences influence the management of these conditions. Graves’ disease is classically managed with one of three treatment options – antithyroid drugs, radioactive iodine, and thyroidectomy. In recent years, there has been a shift towards antithyroid drugs, including long term therapy with these agents, given the advantage of avoiding hypothyroidism and the apparent safety of this approach. In addition, new therapies are (slowly) emerging, focusing on immunomodulation. Technological advances are opening doors to non-pharmaceutical interventions that aim to deal with both structural thyroid abnormalities as well as biochemical abnormalities of hyperthyroidism. Graves’ ophthalmopathy management is guided by its activity and severity status, with treatment options including smoking cessation, control of hyperthyroidism, local eye measures, glucocorticoids, selenium, orbital radiotherapy, and surgery. In addition to these established treatment choices, new immunotherapy-based approaches are being tested. Some of them (tocilizumab and teprotumumab) are very promising but further evaluation is needed before we can establish their role in clinical care. Agents identified as beneficial in Graves’ disease management will likely be tested in Graves’ ophthalmopathy as well. In the coming years, our main clinical responsibility will be to find the proper balance between the benefits and potential risks of these incoming therapies, and to identify the subgroups of patients where this ratio is most likely to favor a safe and successful therapeutic outcome.
Obesity Trends in the Surgical Population at a Large Academic Center: A Comparison between 1989–1991 to 2006–2008 Epochs
Hamlin, R. J., Hofer, Roger E., Schroeder, Darrell R. , Schroeder, Darrell , Šprung, Juraj , Weingarten, Toby N.

Mayo Clinic

Acta Chirurgica Belgica | October 4, 2018 | Volume: 113 | Issue: 6 | Pages: 397-400

10.1080/00015458.2013.11680953 Get It